个人中心 - 老虎社区

Ciboy

IP属地：未知

帖子 · 7帖子 · 7
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- CiboyCiboy
  ·2021-12-23
  Isit a buy?
  非常抱歉，此主贴已删除
  1,918 评论
  1
  分享
  举报
- CiboyCiboy
  ·2021-10-28
  Nice one
  非常抱歉，此主贴已删除
  2,385 1
  2
  分享
  举报
- CiboyCiboy
  ·2021-09-11
  Good buy?
  Why Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote>
  (Update: Sept 10, 2021 at 04:14 a.m. ET) Authorization of the company's COVID-19 vaccine in India a
  Why Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote>
  1,437 评论
  2
  分享
  举报
- CiboyCiboy
  ·2021-08-23
  Thumbs up. Like please
  Pfizer and BioNTech SE shares surged in premarket trading<blockquote>辉瑞和BioNTech SE股价在盘前交易中飙升</blockquote>
  Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval
  Pfizer and BioNTech SE shares surged in premarket trading<blockquote>辉瑞和BioNTech SE股价在盘前交易中飙升</blockquote>
  1,384 1
  2
  分享
  举报
- CiboyCiboy
  ·2021-08-21
  Good article
  非常抱歉，此主贴已删除
  1,138 评论
  2
  分享
  举报
- CiboyCiboy
  ·2021-08-20
  The 3 Rs.
  1,366 评论
  点赞
  分享
  举报
- CiboyCiboy
  ·2021-06-08
  Like and comment
  非常抱歉，此主贴已删除
  963 2
  5
  分享
  举报
暂无粉丝

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3582794558746184","uuid":"3582794558746184","gmtCreate":1619707409658,"gmtModify":1619707409658,"name":"Ciboy","pinyin":"ciboy","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":8,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.16","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.06","exceedPercentage":"60.06%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":691518254,"gmtCreate":1640220048801,"gmtModify":1640220048801,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Isit a buy?","listText":"Isit a buy?","text":"Isit a buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691518254","repostId":"1116093171","repostType":4,"isVote":1,"tweetType":1,"viewCount":1918,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":854001639,"gmtCreate":1635408427135,"gmtModify":1635408427135,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Nice one","listText":"Nice one","text":"Nice one","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/854001639","repostId":"1148392141","repostType":4,"isVote":1,"tweetType":1,"viewCount":2385,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":881119079,"gmtCreate":1631316218291,"gmtModify":1632883268821,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Good buy?","listText":"Good buy?","text":"Good buy?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/881119079","repostId":"1158877090","repostType":4,"repost":{"id":"1158877090","kind":"news","pubTimestamp":1631259068,"share":"https://www.laohu8.com/m/news/1158877090?lang=zh_CN&edition=full","pubTime":"2021-09-10 15:31","market":"us","language":"en","title":"Why Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1158877090","media":"Motley Fool","summary":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India a","content":"<p><i><b>(Update: Sept 10, 2021 at 04:14 a.m. ET)</b></i></p><p><blockquote><i><b>（更新：美国东部时间2021年9月10日凌晨04:14）</b></i></blockquote></p><p>   <b>Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.</b>  <b>Key Points</b></p><p><blockquote><b>该公司的COVID-19疫苗在印度的授权似乎遇到了减速带。</b><b>要点</b></blockquote></p><p> <ul>  <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li>  <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li>  <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li> </ul> <b>What happened</b></p><p><blockquote><ul><li>一份报告称，印度政府已要求Novavax的新冠候选疫苗提供额外数据，然后才能授予紧急使用授权。</li><li>该疫苗在印度的EUA最初预计在10月份，但现在将被推迟。</li><li>考虑到该公司在发达市场的机会更大，此次延迟对Novavax来说并不是一个巨大的打击。</li></ul><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;<i>The Economic Times</i>&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).</p><p><blockquote>本公司之股份<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>截至下午3:25，股价下跌2.6%。美国东部时间周四。这一下降是在<i>经济时报</i>印度政府已要求Novavax的合作伙伴印度血清研究所(SII)提供COVID-19候选疫苗NVX-CoV2373（在印度称为Covovax）的额外数据。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according to<i>The Economic Times</i>&nbsp;article.</p><p><blockquote>SII于8月在印度为Covovax申请了紧急使用授权（EUA）。该提交基于国际临床研究的数据。据报道，该国药品监管机构的一名官员已要求提供在印度进行的疫苗临床试验的数据<i>经济时报</i>文章。</blockquote></p><p> The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.</p><p><blockquote>问题是，SII可能要到下个月才能提交Covovax在印度的临床研究数据。SII首席执行官阿达尔·普纳瓦拉（Adar Poonawalla）在8月份表示，他的组织希望新冠肺炎疫苗将于10月份在印度推出，用于成人，并于2022年第一季度推出儿童。该时间表现在将被推迟。</blockquote></p><p> This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.</p><p><blockquote>这种延迟对Novavax来说并不是一个巨大的打击，疫苗库存相对较小的跌幅就证明了这一点。该公司最大的机会在于包括美国和欧洲在内的发达市场。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.</p><p><blockquote>Novavax预计将在未来几周内在英国申请NVX-CoV2373的EUA。该申请之后，澳大利亚、新西兰和欧盟应迅速提交申请。该公司仍有望在2021年第四季度申请美国EUA。</blockquote></p><p> Novavax fell over 2% in premarket trading.</p><p><blockquote>Novavax在盘前交易中下跌超过2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Slipped Thursday<blockquote>为什么Novavax股价周四下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-09-10 15:31</span>\n</p>\n</h4>\n</header>\n<article>\n<p><i><b>(Update: Sept 10, 2021 at 04:14 a.m. ET)</b></i></p><p><blockquote><i><b>（更新：美国东部时间2021年9月10日凌晨04:14）</b></i></blockquote></p><p>   <b>Authorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.</b>  <b>Key Points</b></p><p><blockquote><b>该公司的COVID-19疫苗在印度的授权似乎遇到了减速带。</b><b>要点</b></blockquote></p><p> <ul>  <li>A report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.</li>  <li>EUA for the vaccine in India was originally expected in October but will now be pushed back.</li>  <li>The delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.</li> </ul> <b>What happened</b></p><p><blockquote><ul><li>一份报告称，印度政府已要求Novavax的新冠候选疫苗提供额外数据，然后才能授予紧急使用授权。</li><li>该疫苗在印度的EUA最初预计在10月份，但现在将被推迟。</li><li>考虑到该公司在发达市场的机会更大，此次延迟对Novavax来说并不是一个巨大的打击。</li></ul><b>发生了什么</b></blockquote></p><p> Shares of&nbsp;<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b> were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by&nbsp;<i>The Economic Times</i>&nbsp;that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).</p><p><blockquote>本公司之股份<b><a href=\"https://laohu8.com/S/NVAX\">Novavax</a></b>截至下午3:25，股价下跌2.6%。美国东部时间周四。这一下降是在<i>经济时报</i>印度政府已要求Novavax的合作伙伴印度血清研究所(SII)提供COVID-19候选疫苗NVX-CoV2373（在印度称为Covovax）的额外数据。</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> SII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according to<i>The Economic Times</i>&nbsp;article.</p><p><blockquote>SII于8月在印度为Covovax申请了紧急使用授权（EUA）。该提交基于国际临床研究的数据。据报道，该国药品监管机构的一名官员已要求提供在印度进行的疫苗临床试验的数据<i>经济时报</i>文章。</blockquote></p><p> The problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.</p><p><blockquote>问题是，SII可能要到下个月才能提交Covovax在印度的临床研究数据。SII首席执行官阿达尔·普纳瓦拉（Adar Poonawalla）在8月份表示，他的组织希望新冠肺炎疫苗将于10月份在印度推出，用于成人，并于2022年第一季度推出儿童。该时间表现在将被推迟。</blockquote></p><p> This delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.</p><p><blockquote>这种延迟对Novavax来说并不是一个巨大的打击，疫苗库存相对较小的跌幅就证明了这一点。该公司最大的机会在于包括美国和欧洲在内的发达市场。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Novavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.</p><p><blockquote>Novavax预计将在未来几周内在英国申请NVX-CoV2373的EUA。该申请之后，澳大利亚、新西兰和欧盟应迅速提交申请。该公司仍有望在2021年第四季度申请美国EUA。</blockquote></p><p> Novavax fell over 2% in premarket trading.</p><p><blockquote>Novavax在盘前交易中下跌超过2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d6cab4a5dd8795f7fda9bc597e6d9d98\" tg-width=\"996\" tg-height=\"568\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/09/09/why-novavax-stock-slipped-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158877090","content_text":"(Update: Sept 10, 2021 at 04:14 a.m. ET)\n\nAuthorization of the company's COVID-19 vaccine in India appears to have hit a speed bump.\n\nKey Points\n\nA report stated that the Indian government has requested additional data for Novavax's COVID-19 vaccine candidate before it can grant Emergency Use Authorization.\nEUA for the vaccine in India was originally expected in October but will now be pushed back.\nThe delay isn't a huge blow for Novavax with the company's bigger opportunities in developed markets.\n\nWhat happened\nShares of Novavax were slipping 2.6% lower as of 3:25 p.m. EDT on Thursday. The decline came following a report by The Economic Times that the Indian government has requested additional data from Novavax's partner, Serum Institute of India (SII), for COVID-19 vaccine candidate NVX-CoV2373 (which is called Covovax in India).\nSo what\nSII filed for Emergency Use Authorization (EUA) in India for Covovax in August. This submission was based on data from international clinical studies. An official with the country's drug regulatory agency has asked for data from a clinical trial of the vaccine conducted in India, according toThe Economic Times article.\nThe problem is that SII likely won't be able to submit data from the clinical studies of Covovax in India until next month. SII CEO Adar Poonawalla stated in August that his organization hoped that the COVID-19 vaccine would be launched in India in October for adults and in the first quarter of 2022 for children. That timeline will now be pushed back.\nThis delay isn't a huge blow for Novavax, as evidenced by the relatively small drop in thevaccine stock. The company's biggest opportunities are in developed markets including the U.S. and Europe.\nNow what\nNovavax expects to file for EUA for NVX-CoV2373 in the United Kingdom within the next few weeks. That filing should be quickly followed by submissions in Australia, New Zealand, and the European Union. The company remains on track to file for U.S. EUA in the fourth quarter of 2021.\nNovavax fell over 2% in premarket trading.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1437,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":835841840,"gmtCreate":1629706755480,"gmtModify":1633683047572,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Thumbs up. Like please","listText":"Thumbs up. Like please","text":"Thumbs up. Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/835841840","repostId":"1104804215","repostType":4,"repost":{"id":"1104804215","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629706373,"share":"https://www.laohu8.com/m/news/1104804215?lang=zh_CN&edition=full","pubTime":"2021-08-23 16:12","market":"us","language":"en","title":"Pfizer and BioNTech SE shares surged in premarket trading<blockquote>辉瑞和BioNTech SE股价在盘前交易中飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1104804215","media":"Tiger Newspress","summary":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval","content":"<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p><p><blockquote>辉瑞和BioNTech SE股价在盘前交易中飙升。食品和药物管理局。据《纽约时报》报道，该公司的目标是在周一全面批准辉瑞的新冠疫苗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p><p><blockquote>据知情人士透露，美国食品药品监督管理局正在推动周一批准辉瑞-BioNTech的两剂新冠肺炎疫苗，进一步加快了该疫苗许可的提前时间表。</blockquote></p><p> Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p><p><blockquote>监管机构正在努力在周五之前完成这一过程，但仍在完成大量文书工作并与该公司进行谈判。未获授权公开谈论该计划的知情人士警告说，如果审查的某些部分需要更多时间，批准可能会推迟到周一之后。</blockquote></p><p> An F.D.A. spokeswoman declined to comment.</p><p><blockquote>食品和药物管理局。发言人拒绝置评。</blockquote></p><p> The agency had recently set an unofficial deadline for approval of around Labor Day.</p><p><blockquote>该机构最近设定了一个非官方的批准截止日期，大约是劳动节。</blockquote></p><p> The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p><p><blockquote>该批准预计将为公共和私人组织的一系列疫苗接种要求铺平道路，这些组织在实施授权之前正在等待最终监管行动。联邦和州卫生官员还希望获得批准的疫苗能够引起一些美国人的兴趣，他们一直犹豫是否要服用仅授权紧急使用的疫苗，最近的民意调查表明了这一现象。</blockquote></p><p> Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month&nbsp;said it planned&nbsp;to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p><p><blockquote>一旦疫苗获得完全批准，一些大学和医院预计将强制接种。五角大楼本月表示，计划“不迟于”下个月中旬强制该国130万现役军人接种新冠疫苗，如果食品和药物管理局批准，则会更早。早些时候的行为。</blockquote></p><p> Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p><p><blockquote>一旦获得批准，辉瑞-BioNTech计划迅速询问食品和药物管理局。批准第三剂作为加强注射。拜登政府周三宣布，从9月20日开始，完全接种疫苗的成年人应在接种第二剂疫苗八个月后准备接种加强针。辉瑞预计将于下周完成提交数据，称这些数据显示第三次注射是安全有效的。</blockquote></p><p> The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p><p><blockquote>食品和药物管理局。上周更新了辉瑞BioNTech和Moderna疫苗的授权，允许一些免疫功能低下的人接种第三剂疫苗，这一决定得到了疾病控制和预防中心的支持。</blockquote></p><p> Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p><p><blockquote>监管机构仍在审查Moderna全面批准其冠状病毒疫苗的申请，可能会在辉瑞-BioNTech做出决定至少几周后做出决定。Moderna计划在9月份提交支持加强注射的数据。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer and BioNTech SE shares surged in premarket trading<blockquote>辉瑞和BioNTech SE股价在盘前交易中飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer and BioNTech SE shares surged in premarket trading<blockquote>辉瑞和BioNTech SE股价在盘前交易中飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-23 16:12</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.</p><p><blockquote>辉瑞和BioNTech SE股价在盘前交易中飙升。食品和药物管理局。据《纽约时报》报道，该公司的目标是在周一全面批准辉瑞的新冠疫苗。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/7fdc37e9193346a16038693153dd045e\" tg-width=\"362\" tg-height=\"125\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.</p><p><blockquote>据知情人士透露，美国食品药品监督管理局正在推动周一批准辉瑞-BioNTech的两剂新冠肺炎疫苗，进一步加快了该疫苗许可的提前时间表。</blockquote></p><p> Regulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.</p><p><blockquote>监管机构正在努力在周五之前完成这一过程，但仍在完成大量文书工作并与该公司进行谈判。未获授权公开谈论该计划的知情人士警告说，如果审查的某些部分需要更多时间，批准可能会推迟到周一之后。</blockquote></p><p> An F.D.A. spokeswoman declined to comment.</p><p><blockquote>食品和药物管理局。发言人拒绝置评。</blockquote></p><p> The agency had recently set an unofficial deadline for approval of around Labor Day.</p><p><blockquote>该机构最近设定了一个非官方的批准截止日期，大约是劳动节。</blockquote></p><p> The approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.</p><p><blockquote>该批准预计将为公共和私人组织的一系列疫苗接种要求铺平道路，这些组织在实施授权之前正在等待最终监管行动。联邦和州卫生官员还希望获得批准的疫苗能够引起一些美国人的兴趣，他们一直犹豫是否要服用仅授权紧急使用的疫苗，最近的民意调查表明了这一现象。</blockquote></p><p> Some universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month&nbsp;said it planned&nbsp;to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.</p><p><blockquote>一旦疫苗获得完全批准，一些大学和医院预计将强制接种。五角大楼本月表示，计划“不迟于”下个月中旬强制该国130万现役军人接种新冠疫苗，如果食品和药物管理局批准，则会更早。早些时候的行为。</blockquote></p><p> Once it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.</p><p><blockquote>一旦获得批准，辉瑞-BioNTech计划迅速询问食品和药物管理局。批准第三剂作为加强注射。拜登政府周三宣布，从9月20日开始，完全接种疫苗的成年人应在接种第二剂疫苗八个月后准备接种加强针。辉瑞预计将于下周完成提交数据，称这些数据显示第三次注射是安全有效的。</blockquote></p><p> The F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.</p><p><blockquote>食品和药物管理局。上周更新了辉瑞BioNTech和Moderna疫苗的授权，允许一些免疫功能低下的人接种第三剂疫苗，这一决定得到了疾病控制和预防中心的支持。</blockquote></p><p> Regulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.</p><p><blockquote>监管机构仍在审查Moderna全面批准其冠状病毒疫苗的申请，可能会在辉瑞-BioNTech做出决定至少几周后做出决定。Moderna计划在9月份提交支持加强注射的数据。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104804215","content_text":"Pfizer and BioNTech SE shares surged in premarket trading.The F.D.A. is aiming to give full approval to Pfizer’s Covid vaccine on Monday,according to the New York Times.\n\nThe Food and Drug Administration is pushing to approve Pfizer-BioNTech’s two-dose Covid-19 vaccine on Monday, further expediting an earlier timeline for licensing the shot, according to people familiar with the agency’s planning.\nRegulators were working to finish the process by Friday but were still working through a substantial amount of paperwork and negotiation with the company. The people familiar with the planning, who were not authorized to speak publicly about it, cautioned that the approval might slide beyond Monday if some components of the review need more time.\nAn F.D.A. spokeswoman declined to comment.\nThe agency had recently set an unofficial deadline for approval of around Labor Day.\nThe approval is expected to pave the way for a series of vaccination requirements by public and private organizations who were awaiting final regulatory action before putting in effect mandates. Federal and state health officials are also hoping that an approved vaccine will draw interest from some Americans who have been hesitant to take one that was only authorized for emergency use, a phenomenon suggested by recent polling.\nSome universities and hospitals are expected to mandate inoculation once a vaccine is fully approved. The Pentagon this month said it planned to make Covid vaccinations mandatory for the country’s 1.3 million active-duty troops “no later” than the middle of next month, or sooner if the F.D.A. acts earlier.\nOnce it obtains the approval, Pfizer-BioNTech is planning to quickly ask the F.D.A. to approve a third dose as a booster shot. The Biden administration on Wednesday announced that fully vaccinated adults should prepare to get booster shots eight months after they received their second doses, beginning Sept. 20. Pfizer is expected to finish submitting data that it says shows a third shot is safe and effective next week.\nThe F.D.A. last week updated its authorizations of Pfizer-BioNTech’s and Moderna’s vaccines to allow third doses for some immunocompromised people, a decision backed by the Centers for Disease Control and Prevention.\nRegulators are still reviewing Moderna’s application for full approval for its coronavirus vaccine, and a decision could come at least several weeks after the one for Pfizer-BioNTech. Moderna is planning to submit its data in support of a booster shot in September.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836511851,"gmtCreate":1629506796773,"gmtModify":1633684407315,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Good article","listText":"Good article","text":"Good article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/836511851","repostId":"2160176501","repostType":4,"isVote":1,"tweetType":1,"viewCount":1138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838259531,"gmtCreate":1629415328623,"gmtModify":1633685078591,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"The 3 Rs.","listText":"The 3 Rs.","text":"The 3 Rs.","images":[{"img":"https://static.tigerbbs.com/2b73a296bec84f92723b409fc422943f","width":"1440","height":"1835"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/838259531","isVote":1,"tweetType":1,"viewCount":1366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":114747983,"gmtCreate":1623108223142,"gmtModify":1634036977719,"author":{"id":"3582794558746184","authorId":"3582794558746184","name":"Ciboy","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582794558746184","idStr":"3582794558746184"},"themes":[],"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/114747983","repostId":"2141342255","repostType":4,"isVote":1,"tweetType":1,"viewCount":963,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":false}